A randomised controlled trial to investigate the clinical and cost effectiveness of Amiodarone vs Beta Blockade for new-onset atrial fibRillation in icU - a Pragmatic sTudy (ABBRUPT)

niversity of Birmingham0 个研究点目标入组 2,560 人开始时间: 2023年9月15日最近更新: 2024年5月21日

适应症

试验速览

暂无简介。

•1. Patients in an adult ICU (age =16 years)
•2. Onset of NOAF during the acute illness (A&E, deterioration on ward, after surgery) having previously been in sinus rhythm and not known to previously have had AF.
•3. A minimum duration of AF of at least 30 minutes
•4. Usual electrolyte management with potassium and magnesium according to site practice
•5. A clinical indication to treat NOAF as determined by the attending clinician

•1. Patients in receipt of amiodarone or a beta-blocker in the previous 24 hours
•2. Patients receiving current concomitant medication with treatments that are contraindicated with the intervention/comparator medications
•3. Patients with a serum potassium of <4 mmol L-1
•4. Patients with a serum magnesium of <1.0 mmol L-1
•5. Patients having undergone cardiac surgery during the current hospital admission, defined as any surgery including stent procedures such as percutaneous coronary interventions or other angioplasty procedures done on the heart muscle, valves or thoracic arteries including the thoracic part of the aorta
•6. Patients with Thyrotoxicosis
•7. Patients where there is a plan for withdrawal of life support therapy within 24 hours
•8. Patients who have had other thoracic surgery that ingresses the thorax
•9. Patients with any other known contraindication or known sensitivity to beta-blockers or amiodarone
•10. Patients with a known pregnancy or patients currently known to be breastfeeding
•11. Patients with any known previous documented history of AF, whether permanent, persistent or paroxysmal

发起方